Amniotics granted U.S. patent for its oncology program AMNI-NK003
October 25, 2022
Amniotics (publ) (Nasdaq Stockholm: AMNI) today announced that the US Patent and Trademark Office (USPTO) has approved a patent application that supports the company’s anti-cancer platform AMNI-NK003. This newly allowed U.S. patent, with application no.16/343617, “Methods and compositions for generating hematopoietic cells” is the first patent for Amniotics to be granted within this field.
Amniotics co-founder Niels Bjarne Woods and colleagues at Lund University have described this novel mechanism that can be used to enhance blood development in vitro to specific blood lineages and thereby increase the production and purity of desired cell types. AMNI-NK003 aims to produce cells with strong antitumor activity, so called Natural Killer (NK) cells. NK cell therapies have been shown in several clinical studies to be effective against both hematological and solid tumors.
“This US patent makes it possible for us to accelerate our anti-cancer platform to generate truly off-the-shelf NK cell therapies to fight cancer. We see great potential in the field, which is the reason why AMNI-NK003 is now a part of our prioritized product portfolio. This milestone has been reached through a team effort, and I want to take the opportunity to thank our co-founder Niels Bjarne Woods, our corporate patent advisor Dominic Davies and our US IP partner Knobbe Martens”, says Marcus Larsson, CEO at Amniotics.
Amniotics anti-cancer program AMNI-NK003 is focusing on generating off-the-shelf Natural Killer (NK) cells from induced pluripotent stem cells (iPS) targeting hematological and solid cancers. NK cell therapy is a new therapeutic approach that uses immune cells to attack tumors. The difficulty to manufacture large quantities of NK cells has hampered the progress. AMNI-NK003 is designed to produce NK cells with high anti-tumor efficacy more efficiently. The program is in pre-clinical phase and next steps include process development under GMP.